For
upper limb spasticity, three of the drug formulations — abobotulinumtoxinA, incobotulinumtoxinA, and onabotulinumtoxinA — are effective in reducing excess muscle tone and should be offered.
Motor function of the affected
upper limb was evaluated mainly using FMA, WMFT, motor activity log (MAL), and the severity of
spasticity was measured with modified Ashworth scale (MAS) at BoNTA injection, discharge and 4 weeks post-discharge.